360b / Shutterstock.com
Bayer has lost an attempt to block a generic version of its cancer drug Nexavar (Sorafenib) in India after the country’s highest court rejected an appeal from the German pharmaceutical company.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Bayer, Nexavar, Supreme Court of India, Natco Pharma, compulsory licence
